Evidence map›Paper›PMID 37604249›Full record

ArticleBiomedical journal2024

Acquired Immune Deficiency Syndrome correlation with SARS-CoV-2 N genotypes.

Iñigo Ximeno-Rodríguez, Irene Blanco-delRío, Egoitz Astigarraga, Gabriel Barreda-Gómez

Open access · goldAbstract read
In one paragraph

Article in Biomedical journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Iñigo Ximeno-RodríguezIxilka Biotech S.L, Bizkaia, Spain. Electronic address: researcharea@ixilka.net.
Irene Blanco-delRíoIxilka Biotech S.L, Bizkaia, Spain.
Egoitz AstigarragaResearch and Development Department, IMG Pharma Biotech S.L, Derio, Bizkaia, Spain.
Gabriel Barreda-GómezResearch and Development Department, IMG Pharma Biotech S.L, Derio, Bizkaia, Spain.
Euskadiko Parke Teknologikoa · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEpigenetics and clinical observations referring to Betacoronavirus lead to the conjecture that Sarbecovirus may have the ability to infect lymphocytes using a different way than the spike protein. In addition to inducing the death of lymphocytes, thus drastically reducing their population and causing a serious immune deficiency, allows it to remain hidden for long periods of latency using them as a viral reservoir in what is named Long-Covid Disease. Exploring possibilities, the hypothesis is focused on that N protein may be the key of infecting lymphocytes.

methodThe present article exhibits a computational assay for the latest complete sequences reported to GISAID, correlating N genotypes with an enhancement in the affinity of the complex that causes immune deficiency in order to determine a good docking with the N protein and some receptors in lymphocytes.

resultsA novel high-interaction coupling of N-RBD and CD147 is presented as the main way of infecting lymphocytes, allowing to define those genotypes involved in their affinity enhancement.

conclusionThe hypothesis is consistent with the mutagenic deriving observed on the in-silico assay, which reveals that genotypes N/120 and N/152 are determinant to reduce the Immune Response of the host infecting lymphocytes, allowing the virus persists indefinitely and causing an Acquire Immune Deficiency Syndrome.

Indexed as

COVID-19GenotypeSARS-CoV-2Acquired Immunodeficiency SyndromeCoronavirus Nucleocapsid ProteinsHumansLymphocytesMolecular Docking SimulationPhosphoproteinsCoronavirus Nucleocapsid Proteinsnucleocapsid phosphoprotein, SARS-CoV-2PhosphoproteinsAcquired Immune Deficiency SyndromeAIDSArtificial intelligenceBioinformaticsLong-Covid diseaseSARS-CoV-2

Identifiers

PMID37604249
PMCPMC11332989
OpenAlexW4386003434

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.